IDH1 and central nervous system cancer: Large-scale drug screening in patient-derived IDH-mutant gliomas identified seven FDA-approved drugs that are active against IDH-mutant gliomas (bortezomib, carfilzomib, daunorubicin, doxorubicin, epirubicin, omacetaxine, and plicamycin) [96].